Cotec Healthcare Ltd. IPO Details
Cotec Healthcare was incorporated on December 22, 1998. The company is India’s second-largest CDMO by number of dosage forms, offering 24 formulation types. Its services include formulation, loan licensing, and commercial manufacturing of off-patent and complex generics across tablets, capsules, injectables, ointments, syrups, and more
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 6.0 M | - | - | ₹2,950.0 M | DRHP DOC |
Cotec Healthcare issue details
Cotec Healthcare has 6.0 M shares on offer
Cotec Healthcare IPO issue size is ₹ 2,950.0 M
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Cotec Healthcare IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Cotec Healthcare NUMBER OF SHARES ON OFFER
Cotec Healthcare FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY25 | 192.2 | 20.0 | 10.6 | -8.6 | 16.4% |
| FY24 | 138.0 | 10.5 | 7.0 | -3.2 | 12.4% |
| FY23 | 82.4 | 5.0 | 6.9 | 2.5 | 11.5% |
Cotec Healthcare INFORMATION ON IPO ISSUE
About Cotec Healthcare
Cotec Healthcare was incorporated on December 22, 1998. The company is India’s second-largest CDMO by number of dosage forms, offering 24 formulation types. Its services include formulation, loan licensing, and commercial manufacturing of off-patent and complex generics across tablets, capsules, injectables, ointments, syrups, and more
Object of the Issue
- Funding capital expenditure requirements for setting up a new project to enhance existing manufacturing capacities and manufacture new products
- General corporate purposes
Cotec Healthcare - PROMOTERS
| Name |
|---|
| Harsh Tiwari |
| Vandana Tiwari |
Cotec Healthcare - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Harsh Tiwari | Chairman & Managing Director |
| Niraj Kumar Shukla | Whole-time Director |
| Ram Nivas Gupta | Whole-time Director |
| Ashoka Kumar Singh | Independent Director |
| Dinesh Chandra Pandey | Independent Director |
| Rekha Pant | Independent Director |
Cotec Healthcare Book Running Lead Manager
Pantomath Capital Advisors Private Limited
cotechealthcare.ipo@pantomathgroup.com
Cotec Healthcare Registrar to the Offer
KFin Technologies Limited
cotechealthcare.ipo@kfintech.com
Cotec Healthcare Strengths
High entry & exit barriers
The company manufactures a broad range of healthcare products, including pharmaceuticals, ayurvedic and herbal preparations, hormonal products, and nutraceuticals. It provides formulation, loan licensing, and commercial manufacturing of off-patent products for institutional and private clients
Scalable infrastructure capabilities
The company operates a 21,871.71 sq. m. manufacturing facility in Roorkee, Uttarakhand, with three dedicated units. Each unit is designed to meet regulatory standards and allow strategic segregation of different pharmaceutical products
In-house formulation
The company collaborates with customers using in-house formulation capabilities and conducts stability studies to ensure product efficacy. Examples of end-to-end developed and commercialized products include Ring Cutter, Sanitiser, and Health Juices
Cotec Healthcare Risks
Contractual obligations
The company’s CDMO agreements include obligations on product quality, recalls, IP protection, termination, and indemnity. Failure to meet these could lead to legal liabilities, reputational damage, and adverse effects on business and financial performance
Regulatory risks
The company is India’s second-largest CDMO by number of dosage forms, having manufactured 410 formulations to date. Developing new formulations is resource-intensive and uncertain, and delays or technical challenges could impact growth and competitiveness
Product safety & liability risks
If the company’s products, or those manufactured for its customers, cause or are perceived to cause severe side effects, it could harm reputation, revenue, and profitability. Such effects may arise from unforeseen side effects, undetected product defects, or misuse, sometimes becoming evident only after market introduction
IPO FAQs
The promoters of the company are Harsh Tiwari and Vandana Tiwari.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.